TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...
European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...
TARRYTOWN, N.Y., Oct. 21, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA® ...
Credit: Getty Images. The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial. The Food and Drug Administration (FDA) has accepted for review the ...
P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...
Credit: Regeneron. Eylea HD is supplied as a sterile, aqueous solution for intravitreal injection in a single-dose vial containing 8mg of aflibercept. The Food and Drug Administration (FDA) has ...
The results for a proposed aflibercept (Eylea) biosimilar and an accepted ranibizumab (Lucentis) biosimilar were presented at Euretina Congress 2023. Trial results presented at Euretina Congress 2023 ...
Please provide your email address to receive an email when new articles are posted on . Investigators retrospectively analyzed visual and anatomic outcomes of patients who were attempted to be weaned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results